Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:04:34·⟳ 抓取 19:05:07 +33s·⚡ 决策 10-12 19:06:37 +1m30s·15.3 天前
ANI制药ILUVIEN葡萄膜炎植入剂4期试验双终点达标，但适应症已于2025年获批、6个月数据7月已披露
这是一款2025年即已获批适应症的4期上市后确认性试验，阳性6个月顶线早在2026-07-13由公司新闻稿披露，本次AAO仅为24个月随访的学术更新，不构成新的批准、商业化或财务指引增量；ILUVIEN眼科业务在以仿制药+罕见病(Cortrophin Gel)为主导的ANI中占比小，盘前股价反而下跌约1.9%，缺乏正期望edge。
📄 原文Investing.com↗ 原文
ANI reports positive results from uveitis implant trial
By Investing.com Advertisement Advertisement ANI reports positive results from uveitis implant trial Company News Publi…
不做 ANI Pharmaceuticals, Inc.（ANIP.US）
无新增基本面事实：葡萄膜炎适应症2025年已获批，6个月阳性顶线2026-07-13已公告，本次仅为AAO会议24个月随访的批准后确认性数据；ILUVIEN在17亿美元市值中占比小、无销售/指引增量，盘前股价反跌约1.9%，不具备事件驱动edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ILUVIEN葡萄膜炎适应症2025年已获FDA批准、6个月阳性数据2026年7月已发公告，本次AAO 24个月数据属批准后确认性学术更新，无新增监管或业绩催化，盘前还下跌约1.9%，不做。
消息传播链
- Investing.com转述AAO 2026会议上公布的24个月完整数据；为AI辅助生成的媒体稿，非一手公司披露。盘前ANIP报约72.5美元，较前收73.89跌约1.9%
关键理由
- 双终点达标、79.6%患者24个月无复发，安全性可管理，对ILUVIEN在葡萄膜炎领域的临床证据有边际正面意义
主要风险
- 若市场把24个月长期数据解读为新的销售放量催化，可能出现情绪性反弹，但缺乏新增基本面支撑，持续性存疑
- 治疗相关不良事件29%、近15%研究眼需白内障手术，长期安全性争议可能限制渗透
反向证据
- 做多前查反向 · 来源 web · 日期 2026-05-08 · 影响 weakens
公司2026年增长叙事由罕见病Cortrophin Gel(Q1净收入7510万美元,+42%)与仿制药驱动并上调全年指引，ILUVIEN眼科非主要增长引擎，本次数据无业绩指引配套
检索:ANI Pharmaceuticals 2026 guidance ILUVIEN uveitis revenue contribution 原文 ↗
先例如何影响了这次决策
对本次决策的影响:支持AVOID：不设做多腿，不博会议行情
方向:无足够对齐先例；本质是已披露顶线后的长期随访学术更新，不具备事件驱动型临床读数的预期差
涨幅量级:未做event_study：无新增监管/业绩里程碑，盘前负反应已表明市场不视其为可交易利好，缺乏校准幅度的基础
形态:批准后4期/亚组长期数据的学术展示通常不产生独立行情，尤其在顶线数据已先行公告时
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`ani pharmaceuticals iluvien uveitis synchronicity phase 4 trial results | anip fluocinolone acetonide implant uveitis phase 4 endpoints aao 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当 - web_search 成功 doubao_search · 3,591 ms
豆包搜索结果（原始查询:ANI Pharmaceuticals ILUVIEN uveitis FDA approval 2025 SYNCHRONICITY Phase 4；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 394 ms
{
原文全文
展开原文 · 7,452 字
ANI reports positive results from uveitis implant trial By Investing.com
Advertisement
Advertisement
ANI reports positive results from uveitis implant trial
Company News
Published
Oct 12, 2026, 07:04 AM
ANI reports positive results from uveitis implant trial
View all comments (0)
0
ANI reports positive results from uveitis implant trial
View all comments (0)
0
© Reuters
In this article:
ANIP
+
2.65%
PRINCETON, N.J. - ANI Pharmaceuticals Inc. (
NASDAQ:ANIP
) announced Thursday that its Phase 4 clinical trial of fluocinolone acetonide intravitreal implant met both primary endpoints in patients with chronic non-infectious uveitis affecting the posterior segment of the eye.
The SYNCHRONICITY trial, which enrolled 108 patients in the U.S., showed statistically significant improvements at six months in both best corrected visual acuity letter score and central subfield thickness, according to a company press release statement. These improvements were maintained at 24 months.
Patients in the trial gained an average of 3.6 letters in visual acuity at six months and 5.5 letters at 24 months. Central subfield thickness decreased by an average of 157.5 microns at six months and 171.2 microns at 24 months.
The study found that 79.6% of patients experienced no recurrence of inflammation over the 24-month period. Among those who did experience recurrence, the median time to recurrence was 168 days.
The trial’s safety profile showed that 29% of patients experienced treatment-related adverse events. The most common were ocular hypertension in 6% of patients, cataract in 5%, and reduced visual acuity in 5%. IOP-lowering medication was required by 29.6% of patients, while 7.4% needed surgical intervention for elevated intraocular pressure. Cataract surgery was performed in 14.8% of study eyes.
The results were presented Wednesday at the American Academy of Ophthalmology 2026 Meeting in New Orleans by Dr. David R.P. Almeida, the study’s principal investigator.
ILUVIEN was approved by the FDA in 2014 for diabetic macular edema treatment. In 2025, the FDA expanded the label to include treatment of chronic non-infectious uveitis affecting the posterior segment.
The study population had a mean age of 64 years, with 65% being female. Most patients in the study were treated by retina specialists.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ANI reports positive results from uveitis implant trial
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,694.60
+39.4
+0.08%
US 500
7,813.70
+2.2
+0.03%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.50
+0.66
+4.45%
Dollar Index
102.21
+0.188
+0.18%
Crude Oil WTI Futures
92.92
+1.07
+1.16%
Brent Oil Futures
105.97
+1.25
+1.19%
Natural Gas Futures
3.145
-0.075
-2.33%
Gold Futures
4,199.26
-17.04
-0.40%
Silver Futures
60.90
-0.148
-0.24%
Copper Futures
6.7665
+0.0745
+1.11%
US Soybeans Futures
1,282.88
-8.13
-0.63%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.53
-0.06
-0.06%
Euro Bund Futures
121.05
-0.03
-0.03%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Premarket movers: Iren jumps on Anthropic deal, CCC surges on buyout talks
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
ANI reports positive results from uveitis implant trial
Company News
Published
Oct 12, 2026, 07:04 AM
ANI reports positive results from uveitis implant trial
View all comments (0)
0
ANI reports positive results from uveitis implant trial
View all comments (0)
0
© Reuters
In this article:
ANIP
+
2.65%
PRINCETON, N.J. - ANI Pharmaceuticals Inc. (
NASDAQ:ANIP
) announced Thursday that its Phase 4 clinical trial of fluocinolone acetonide intravitreal implant met both primary endpoints in patients with chronic non-infectious uveitis affecting the posterior segment of the eye.
The SYNCHRONICITY trial, which enrolled 108 patients in the U.S., showed statistically significant improvements at six months in both best corrected visual acuity letter score and central subfield thickness, according to a company press release statement. These improvements were maintained at 24 months.
Patients in the trial gained an average of 3.6 letters in visual acuity at six months and 5.5 letters at 24 months. Central subfield thickness decreased by an average of 157.5 microns at six months and 171.2 microns at 24 months.
The study found that 79.6% of patients experienced no recurrence of inflammation over the 24-month period. Among those who did experience recurrence, the median time to recurrence was 168 days.
The trial’s safety profile showed that 29% of patients experienced treatment-related adverse events. The most common were ocular hypertension in 6% of patients, cataract in 5%, and reduced visual acuity in 5%. IOP-lowering medication was required by 29.6% of patients, while 7.4% needed surgical intervention for elevated intraocular pressure. Cataract surgery was performed in 14.8% of study eyes.
The results were presented Wednesday at the American Academy of Ophthalmology 2026 Meeting in New Orleans by Dr. David R.P. Almeida, the study’s principal investigator.
ILUVIEN was approved by the FDA in 2014 for diabetic macular edema treatment. In 2025, the FDA expanded the label to include treatment of chronic non-infectious uveitis affecting the posterior segment.
The study population had a mean age of 64 years, with 65% being female. Most patients in the study were treated by retina specialists.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ANI reports positive results from uveitis implant trial
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,694.60
+39.4
+0.08%
US 500
7,813.70
+2.2
+0.03%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.50
+0.66
+4.45%
Dollar Index
102.21
+0.188
+0.18%
Crude Oil WTI Futures
92.92
+1.07
+1.16%
Brent Oil Futures
105.97
+1.25
+1.19%
Natural Gas Futures
3.145
-0.075
-2.33%
Gold Futures
4,199.26
-17.04
-0.40%
Silver Futures
60.90
-0.148
-0.24%
Copper Futures
6.7665
+0.0745
+1.11%
US Soybeans Futures
1,282.88
-8.13
-0.63%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.53
-0.06
-0.06%
Euro Bund Futures
121.05
-0.03
-0.03%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Premarket movers: Iren jumps on Anthropic deal, CCC surges on buyout talks
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
63afdf7288· 2026-10-12 19:06 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前